Navigation Links
Cases of drug-resistant superbug significantly rise in southeastern US
Date:7/16/2014

CHICAGO (July 16, 2014) Cases of the highly contagious, drug-resistant bacteria, carbapenem-resistant Enterobacteriaceae (CRE), have increased fivefold in community hospitals in the Southeastern United States, according to a new study published in the August issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

"This dangerous bacteria is finding its way into healthcare facilities nationwide. Even this marked increase likely underestimates the true scope of the problem given variations in hospital surveillance practices," said Joshua Thaden, MD, a lead author of the study. "A CRE epidemic is fast approaching. We must take immediate and significant action in order to limit the transmission of these dangerous pathogens throughout our hospitals and acute care facilities."

CRE are a class of highly antibiotic-resistant bacteria that are not susceptible to most commonly-used antibiotics. Labeled "one of the three greatest threats to human health" by the World Health Organization, these dangerous pathogens can cause infections in the urinary tract, lungs, blood, and other areas. Patients with CRE infections have high risk of mortality, with at least 48 percent of cases proving fatal.

Over the five-year study period, researchers identified 305 unique patients with CRE through the Duke Infection Control Outreach Network (DICON), a cluster of 25 community hospitals in the Southeastern U.S. In this retrospective cohort, infection prevention professionals identified cases via prospective surveillance using standardized protocols in all hospitals. However, the majority of microbiology laboratories in the study had not adopted the most recent, and more sensitive, guidelines for detecting the bacteria. In hospitals that had adopted the guidelines, the rate of CRE detection was more than three times higher.

Half of the patients with CRE were symptomatic (59 percent) and nearly all cases were healthcare-associated (60 percent community-onset, healthcare-associated, 34 percent hospital onset). The higher rate of infection was found to stem from a combination of factors, including:

  • Increased use of broad-spectrum antibiotics;
  • Ease of which CRE enzymes could be transmitted among bacteria; and
  • Increased transmission between long-term acute care facilities and community hospitals.

"This is a wake up call for community hospitals. More must be done to prepare and respond to CRE, specifically infection control to limit person-to-person transmission and improved laboratory detection," said Thaden.

In a commentary accompanying the study, Christopher Pfeiffer, MD, noted increased financial and staffing shortages as two challenges community hospitals faced in trying to prevent transmission of the superbug. Pfeiffer offered, "CRE prevention and control could benefit from regional collaborative networks armed with knowledge and resources to assist individual facilities and coordinate between facilities, which have been successful in the control of other antibiotic-resistant bacteria."

In 2012, the Centers for Disease Control and Prevention developed a CRE toolkit to help protect patients and prevent transmission.The toolkit is available at http://www.cdc.gov/hai/organisms/cre/cre-toolkit.


'/>"/>

Contact: Tamara Moore
tmoore@gymr.com
202-745-5114
Society for Healthcare Epidemiology of America
Source:Eurekalert

Related medicine news :

1. Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com
2. Six cases where big data can reduce healthcare costs
3. EuroPCR 2014 showcases technological advances in complex cardiovascular interventions
4. Fourfold increase in the rate of diagnosed cases of Celiac disease in the UK
5. AGA showcases its commitment to improving the pipeline of minority researchers
6. Stanford scientists identify source of most cases of invasive bladder cancer
7. RF Safe Launches Smartphone Flip Cases for Apple iPhone to Shield Cell Phone Radiation
8. RF Safe Launches Samsung Smartphone Flip Cases To Shield Cell Phone Radiation
9. New Order Issued in GYNECARE PROLIFT Transvaginal Mesh Lawsuit Consolidation Ensures Cases Move Forward, Rottenstein Law Group LLP Reports
10. Beautiful Apple iPhone 5 Hard Cases Unveiled By Skmen.com
11. Discounted iPad Mini Leather Cases On Online At Skmen.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... for-profit and nonprofit hospitals and health systems in the nation and help their ... institutions, led professional organizations and been instrumental in developing successful hospital and health ...
(Date:5/23/2017)... City (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 ... Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: ... serve earlier this month as a Guest Speaker and Contributor to a weeklong series ... and Common Purpose. , Walter Schindler and SAIL Capital ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
Breaking Medicine Technology: